Apichart Suksamrarn

Prof. Apichart Suksamrarn

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2004 in Archives of Pharmacal Research
Verified
Journal Article
Closed access
PDF file
ASApichart Suksamrarn
Apichart Suksamrarn
ACApinya Chotipong
Apinya Chotipong
TSTananit Suavansri
Tananit Suavansri
SBSomnuk Boongird
Somnuk Boongird
PTPuntip Timsuksai
Puntip Timsuksai
ACAporn Chuaynugul
Aporn Chuaynugul

1 July 2008 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
ASApichart Suksamrarn
Apichart Suksamrarn
MPMathurose Ponglikitmongkol
Mathurose Ponglikitmongkol
KWKanjana Wongkrajang
Kanjana Wongkrajang
ACAnon Chindaduang
Anon Chindaduang
SKSuthadta Kittidanairak
Suthadta Kittidanairak
PPPawinee Piyachaturawat
Pawinee Piyachaturawat

19 December 2014 in Journal of Plant Growth Regulation
Verified
Journal Article
Closed access
PDF file
Jutiporn ThussagunpanitJutiporn Thussagunpanit
Jutiporn Thussagunpanit
KJKanapol Jutamanee
Kanapol Jutamanee
LKLily Kaveeta
Lily Kaveeta
WCWitith Chai-Arree
Witith Chai-Arree
PPPorn Pankean
Porn Pankean
ASApichart Suksamrarn
Apichart Suksamrarn

12 October 2012 in BMC Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
SDSuwit Duangmano
Suwit Duangmano
PSPhorntip Sae-Lim
Phorntip Sae-Lim
ASApichart Suksamrarn
Apichart Suksamrarn
FDFrederick Domann
Frederick Domann
PPPimpicha Patmasiriwat
Pimpicha Patmasiriwat
Background: Cucurbitacin B, an oxygenated tetracyclic triterpenoid compound extracted from the Thai medicinal plant Trichosanthes cucumerina L., has been reported to have several biological activities including anti-inflammatory, antimicrobial and anticancer. Cucurbitacin B is great of interest because of its biological activity. This agent inhibits growth of various types of human cancer cells lines. Methods: In this study, we explored the novel molecular response of cucurbitacin B in human breast cancer cells, MCF-7 and MDA-MB-231. The growth inhibitory effect of cucurbitacin B on breast cancer cells was assessed by MTT assay. The effects of cucurbitacin B on microtubules morphological structure and tubulin polymerization were analyzed using immunofluorescence technique and tubulin polymerization assay kit, respectively. Proteomic analysis was used to identify the target-specific proteins that involved in cucurbitacin B treatment. Some of the differentially expressed genes and protein products were validated by real-time RT-PCR and western blot analysis. Cell cycle distributions and apoptosis were investigated using flow cytometry. Results: Cucurbitacin B exhibited strong antiproliferative effects against breast cancer cells in a dose-dependent manner. We show that cucurbitacin B prominently alters the cytoskeletal network of breast cancer cells, inducing rapid morphologic changes and improper polymerization of the microtubule network. Moreover, the results of 2D-PAGE, real-time RT-PCR, and western blot analysis revealed that the expression of nucleophosmin/B23 and c-Myc decreased markedly after cucurbitacin B treatment. Immunofluorescence microscopy showed that cucurbitacin B induced translocation of nucleophosmin/B23 from the nucleolus to nucleoplasm. Treatment with cucurbitacin B resulted in cell cycle arrest at G2/M phase and the enhancement of apoptosis. Conclusions: Our findings suggest that cucurbitacin B may inhibit the proliferation of human breast cancer cells through disruption of the microtubule network and down-regulation of c-Myc and nucleophosmin/B23 as well as the perturbation in nucleophosmin/B23 trafficking from the nucleolus to nucleoplasm, resulting in G2/M arrest.

31 January 2002 in Planta Medica
Verified
Journal Article
Closed access
PDF file
ASApichart Suksamrarn
Apichart Suksamrarn
SKS. Kumpun
S. Kumpun
KKK. Kirtikara
K. Kirtikara
BYB. Yingyongnarongkul
B. Yingyongnarongkul
SSS. Suksamrarn
S. Suksamrarn
A new iridoid, pedunculariside, together with the known iridoid agnuside were isolated from the butanol extract of Vitex peduncularis stem bark. Both pedunculariside and agnuside showed preferential inhibition of COX-2, with IC50 values of 0.15 ± 0.21 mg/ml and 0.026 ± 0.015 mg/ml respectively, while having only small inhibitory effects on COX-1. Both compounds did not exhibit cytotoxicity against vero cells.

Verified
Journal Article
Open access
PDF file
SDSuwit Duangmano
Suwit Duangmano
SDSumana Dakeng
Sumana Dakeng
WJWeena Jiratchariyakul
Weena Jiratchariyakul
ASApichart Suksamrarn
Apichart Suksamrarn
DSDuncan Smith
Duncan Smith
PPPimpicha Patmasiriwat
Pimpicha Patmasiriwat
Naturally occurring cucurbitacins have been shown to have anticancer, antimicrobial and anti-inflammatory activities. In this study, we determined the effects of cucurbitacin B extracted from the Thai herb Trichosanthes cucumerina L. on telomerase regulation in three human breast cancer cell lines (T47D, SKBR-3, and MCF-7) and a mammary epithelium cell line (HBL-100). Cell viability after treatment with cucurbitacin B, which is an active ingredient of this herb, was assessed. Telomeric Repeat Amplification Protocol (TRAP) assays and RT-PCR (qualitative and realtime) were performed to investigate activity of telomerase as well as expression of human telomerase reverse transcriptase (hTERT) and c-Myc. The c-Myc protein level was also determined in SKBR-3 and HBL-100 cells. Our results show that the cucurbitacin B inhibits growth and telomerase activity in the three breast cancer cell lines and exerts an obvious inhibitory effect in the estrogen receptor (ER)-negative breast cancer SKBR-3 cells. The expression of hTERT and c-Myc were also inhibited by cucurbitacin B, In addition, a clear reduction of c-Myc protein was observed after treatment in SKBR-3 cells even with a concentration of cucurbitacin B that was ten-times lower compared to the concentration used for HBL-100. Our findings imply that cucurbitacin B exerts an anticancer effect by inhibiting telomerase via down regulating both the hTERT and c-Myc expression in breast cancer cells.